These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Broadly neutralizing antibodies and the promise of universal vaccines: where are we now? Hefferon KL Immunotherapy; 2014; 6(1):51-7. PubMed ID: 24341884 [TBL] [Abstract][Full Text] [Related]
3. Broadly neutralizing antibodies against HIV-1: templates for a vaccine. van Gils MJ; Sanders RW Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615 [TBL] [Abstract][Full Text] [Related]
4. GP120: target for neutralizing HIV-1 antibodies. Pantophlet R; Burton DR Annu Rev Immunol; 2006; 24():739-69. PubMed ID: 16551265 [TBL] [Abstract][Full Text] [Related]
5. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Haynes BF; Montefiori DC Expert Rev Vaccines; 2006 Aug; 5(4):579-95. PubMed ID: 16989638 [TBL] [Abstract][Full Text] [Related]
6. Broad-range neutralizing anti-influenza A human monoclonal antibodies: new perspectives in therapy and prophylaxis. Clementi N; Criscuolo E; Castelli M; Clementi M New Microbiol; 2012 Oct; 35(4):399-406. PubMed ID: 23109007 [TBL] [Abstract][Full Text] [Related]
7. Importance of conformation on the neutralizing antibody response to HIV-1 gp120. Steimer KS; Haigwood NL Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963 [TBL] [Abstract][Full Text] [Related]
8. Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro. Quakkelaar ED; Bunnik EM; van Alphen FP; Boeser-Nunnink BD; van Nuenen AC; Schuitemaker H Virology; 2007 Jul; 363(2):447-53. PubMed ID: 17355886 [TBL] [Abstract][Full Text] [Related]
9. Human 4F5 single-chain Fv antibody recognizing a conserved HA1 epitope has broad neutralizing potency against H5N1 influenza A viruses of different clades. Zhang X; Qi X; Zhang Q; Zeng X; Shi Z; Jin Q; Zhan F; Xu Y; Liu Z; Feng Z; Jiao Y Antiviral Res; 2013 Aug; 99(2):91-9. PubMed ID: 23680121 [TBL] [Abstract][Full Text] [Related]
10. Model for competition from self during passive immunization, with application to broadly neutralizing antibodies for HIV. Ali Tabei SM; Li Y; Weigert M; Dinner AR Vaccine; 2012 Jan; 30(3):607-13. PubMed ID: 22119591 [TBL] [Abstract][Full Text] [Related]
11. Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection. Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; van Nuenen AC; Schuitemaker H Virology; 2009 Aug; 390(2):348-55. PubMed ID: 19539340 [TBL] [Abstract][Full Text] [Related]
12. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. Jegaskanda S; Job ER; Kramski M; Laurie K; Isitman G; de Rose R; Winnall WR; Stratov I; Brooks AG; Reading PC; Kent SJ J Immunol; 2013 Feb; 190(4):1837-48. PubMed ID: 23319732 [TBL] [Abstract][Full Text] [Related]
13. Antibodies against swine influenza virus neutralize the pandemic influenza virus A/H1N1. Tsukamoto M; Hiroi S; Adachi K; Kato H; Inai M; Konishi I; Tanaka M; Yamamoto R; Sawa M; Handharyani E; Tsukamoto Y Mol Med Rep; 2011; 4(2):209-14. PubMed ID: 21468553 [TBL] [Abstract][Full Text] [Related]
14. Trends in development of the influenza vaccine with broader cross-protection. Stropkovská A; Janulíková J; Varecková E Acta Virol; 2010; 54(1):7-19. PubMed ID: 20201609 [TBL] [Abstract][Full Text] [Related]
15. Passive immunization with human neutralizing monoclonal antibodies against HIV-1 in macaque models: experimental approaches. Ruprecht RM Methods Mol Biol; 2009; 525():559-66, xiv. PubMed ID: 19252837 [TBL] [Abstract][Full Text] [Related]
16. Variable epitope libraries: new vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response. Charles-Niño C; Pedroza-Roldan C; Viveros M; Gevorkian G; Manoutcharian K Vaccine; 2011 Jul; 29(32):5313-21. PubMed ID: 21600948 [TBL] [Abstract][Full Text] [Related]
17. One step closer to universal influenza epitopes. Li OT; Poon LL Expert Rev Anti Infect Ther; 2009 Aug; 7(6):687-90. PubMed ID: 19681695 [TBL] [Abstract][Full Text] [Related]
18. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P). Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906 [TBL] [Abstract][Full Text] [Related]
19. Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies. Quakkelaar ED; van Alphen FP; Boeser-Nunnink BD; van Nuenen AC; Pantophlet R; Schuitemaker H J Virol; 2007 Aug; 81(16):8533-42. PubMed ID: 17522228 [TBL] [Abstract][Full Text] [Related]
20. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. Ferrantelli F; Rasmussen RA; Buckley KA; Li PL; Wang T; Montefiori DC; Katinger H; Stiegler G; Anderson DC; McClure HM; Ruprecht RM J Infect Dis; 2004 Jun; 189(12):2167-73. PubMed ID: 15181562 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]